ChromaDex Corporation - CDXC STOCK NEWS

ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, will participate in Renmark's Virtual Non-Deal Roadshow Series on Thursday, August 29, 2024, at 2:00 PM EDT. The event will feature a presentation by key executives, including CEO Rob Fried, Interim CFO James Lee, and VP Finance Wesley Yu.

The live presentation will cover ChromaDex's latest investor information, followed by a Q&A session. While live event registration may be , a replay will be available on the company's investor website. Interested parties can register for the event using the provided link, and are advised to use the latest version of Google Chrome for optimal connectivity.

This virtual roadshow offers an opportunity for stakeholders, investors, and followers to gain insights into ChromaDex's current initiatives and future prospects in the field of healthy aging and NAD+ research.

ChromaDex Corp. (NASDAQ:CDXC) has secured U.S. Patent number 10,000,520 C1 for the composition of matter of salt forms of NMNH (dihydronicotinamide mononucleotide), a precursor to NAD+. This patent, co-owned with Queen's University Belfast, grants ChromaDex exclusive rights to the disodium salt form of NMNH. The company now has over 80 patents related to NAD+ precursors, including its flagship ingredient Niagen® (nicotinamide riboside).

NMNH is distinct from NMN, which was banned as a dietary supplement by the FDA in 2022. While NMNH has shown promise in preclinical studies, further research is needed to determine its oral bioavailability and safety as a dietary supplement. Currently, NMNH's legal status as a dietary supplement is questionable due to lack of proper FDA notification as a new dietary ingredient (NDI).

ChromaDex Corp. (NASDAQ:CDXC) reported strong Q2 2024 financial results, with total net sales of $22.7 million, up 12% year-over-year. Tru Niagen® sales reached $18.6 million, a 10% increase. The company achieved a gross margin of 60.2% and reduced operating expenses by $0.7 million compared to the prior year quarter. ChromaDex reported an approximately breakeven net loss and positive Adjusted EBITDA of $1.6 million.

Key developments include receiving U.S. FDA Orphan Drug Designation for nicotinamide riboside chloride to treat Ataxia Telangiectasia, and launching Niagen+, a pharmaceutical-grade product line. The company also introduced Niagen+ NAD+ Test Kits for healthcare practitioners. For the full year 2024, ChromaDex expects 10-15% revenue growth and slightly improved gross margins.

ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, announces its participation in Canaccord Genuity's 44th Annual Growth Conference from August 13-15, 2024, in Boston. CEO Rob Fried and Interim CFO James Lee will present on August 14 and conduct one-on-one meetings throughout the event.

This prestigious conference, a 44-year cornerstone for industry leaders and investors, provides ChromaDex an opportunity to showcase its latest developments, strategic initiatives, and growth prospects. Interested parties can arrange meetings through the conference website or their CG representative.

ChromaDex's involvement underscores its commitment to engaging with investors and industry experts, potentially impacting its market position and future growth strategies in the healthy aging sector.

ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, has announced its Q2 2024 financial results conference call. The call is scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET. Financial results will be released via press release after market close on the same day. Investors can join the call using the toll-free number 1-888-596-4144 (Conference ID: 8584242) or via webcast. Management will discuss Q2 results and provide a general business update. A replay will be available until August 14, 2024. This event offers investors an opportunity to gain insights into ChromaDex's financial performance and future outlook.

ChromaDex Corp. (NASDAQ:CDXC) has launched the Niagen+ NAD+ Test Kit, exclusively available through its healthcare practitioner (HCP) channel. This innovative kit allows practitioners to measure patient blood NAD+ levels, enabling more personalized protocols using ChromaDex's NAD+-boosting products, Tru Niagen® and Niagen+.

The test kit features advanced dried blood spot (DBS) assay technology, ensuring NAD+ sample stability during transport. Analysis is conducted using high-resolution liquid chromatography/tandem mass spectrometry (LC-MS/MS) at a CLIA and CAP accredited laboratory. Results are available to both patients and doctors in about two weeks through the 1health platform.

This launch represents a significant advancement in NAD+ therapy, allowing practitioners to track NAD+ changes over time and create more effective patient protocols.

ChromaDex Corp. (NASDAQ:CDXC) has appointed Carlos Lopez as Senior Vice President, General Counsel, effective July 22, 2024. Lopez, a distinguished legal professional with expertise in the dietary supplements industry, will oversee the organization's legal function, including corporate governance, securities, intellectual property, and litigation. He will report directly to CEO Rob Fried.

Prior to joining ChromaDex, Lopez served as Vice President, General Counsel at The Vitamin Shoppe and has been on the board of The Natural Products Association. CEO Rob Fried expressed confidence in Lopez's expertise to help achieve ChromaDex's ambitious plans. Lopez stated his excitement to join ChromaDex, recognizing it as the gold-standard company pioneering NAD+ research and innovation.

ChromaDex Corp. (NASDAQ:CDXC) announces the debut of pharmaceutical-grade Niagen® (nicotinamide riboside chloride) for intravenous and injectable use at leading wellness clinics in August. Wells Pharma of Houston, a U.S. FDA-registered 503B outsourcing facility, will compound and distribute Niagen+ to select IV clinics.

Niagen IV offers superior tolerability, a 75% shorter infusion time, and a higher, faster rise in NAD+ blood levels compared to standard NAD+ IV treatments. With the global intravenous hydration therapy market valued at over $2.32 billion in 2022, ChromaDex is well-positioned to capture a significant share with its new product.

The company has secured orders beyond August and plans to expand into medical spas, with 11,000 locations in the US alone. Several prominent wellness clinics, including Clean Market/NutriDrip, Next Health, REVIV, and Restore Hyper Wellness, have expressed enthusiasm for the launch of Niagen+.

ChromaDex announced its inclusion in the Russell 2000® Index, effective July 1, 2024, as part of the annual Russell indexes reconstitution. This milestone, highlighted by CEO Rob Fried, marks ChromaDex's sustained growth and leadership in NAD+ research. ChromaDex's flagship product, Tru Niagen®, is renowned for its scientific rigor and quality standards, offering a clinically proven NAD+ supplement to combat age-related health decline. The Russell 2000 Index includes the 4,000 largest U.S. stocks, and ChromaDex's inclusion reflects its robust market capitalization and potential to drive long-term shareholder value.